ICS and LABA only drugs

Question 1

beclomethasone brand

Answer 1

QVAR

Question 2

beclomethasone (qvar) dosage form

Answer 2

redihaler (mdi)
40 or 80 mcg/inhalation

Question 3

ciclesonide brand

Answer 3

alvesco

Question 4

beclomethasone (qvar) dosing in 5-11 yos

Answer 4

40-80 mcg inhaled bid

Question 5

beclomethasone (qvar) dosing in adults

Answer 5

40-320 mcg inhaled bid

Question 5

budesonide brand

Answer 5

pulmicort
pulmicort respules

Question 5

budesonide (pulmicort) dosage form

Answer 5

flexhaler
90 or 180 mcg/inhalation

Question 5

budesonide (pulmicort) dosing in 5-11 yos

Answer 5

90-360 mcg inhaled bid

Question 6

budesonide (pulmicort) dosing in adults

Answer 6

90-720 mcg inhaled bid

Question 7

budesonide (pulmicort respules) dosage form

Answer 7

nebulizer solution
0.25mg/2mL
0.5mg/2mL
1mg/2mL

Question 8

ciclesonide (alvesco) dosage form

Answer 8

HFA
80 or 160 mcg/inhalation

Question 9

fluticasone propionate brand

Answer 9

flovent
armonAir diginhaler

Question 10

fluticasone propionate (flovent, armonair diginhaler) dosage form

Answer 10

HFA - 44, 110, or 220 mcg/inhalation
DPI - 50, 100, or 250 mcg/inhalation
aerosol powder inhaler - 55, 113, 232 mcg/actuation

Question 11

fluticasone propionate (flovent, ArmonAir Diginhaler) dosing in 0-4 yos

Answer 11

only over 4 yos
HFA - 88 mcg bid
DPI - 50 mcg bid

Question 12

budesonide (pulmicort respules) dosing in 0-4 yos

Answer 12

0.25 to 1 mg/day qd or divided bid

Question 13

budesonide (pulmicort respules) dosing in 5-11 yos

Answer 13

0.5 to 2 mg per day qd or divided bid

Question 14

ciclesonide (alvesco) dosing in 5-11 yos

Answer 14

only over 6 yos
80 to 160 mcg qd

Question 15

fluticasone propionate (flovent, armonair diginhaler) dosing in 5-11 yos

Answer 15

HFA - 44 to 88 mcg inhaled bid
DPI - 50 to 100 mcg inhaled bid

Question 16

fluticasone propionate (flovent, armonair diginhaler) dosing in adults

Answer 16

HFA - 44 to 220 mcg inhaled bid
DPI - 50 to 250 mcg inhaled bid
MDPI - 55 to 232 mcg inhaled bid

Question 17

ciclesonide (alvesco) dosing in adults

Answer 17

80 to 320 mcg inhaled bid

Question 18

fluticasone furoate brand

Answer 18

arnuity ellipta

Question 19

fluticasone furoate (arnuity ellipta) dosage form

Answer 19

50, 100, and 200 mcg per inhalation

Question 20

mometasone (asmanex) dosage forms

Answer 20

HFA - 50, 100, and 200 mcg/inhalation
twisthaler - 110 and 220 mcg/inhalation

Question 21

mometasone brand

Answer 21

asmanex

Question 22

fluticasone fuorate (arnuity ellipta) dosing in 4-11 yos

Answer 22

50 mcg qd

Question 23

fluticasone fuorate (arnuity ellipta) dosing in adults

Answer 23

100 to 200 mcg inhaled qd

Question 24

mometasone (asmanex) dosing in 4-11 yos

Answer 24

HFA - 100 mcg bid Twisthaler - 110 mcg qpm

Question 25

mometasone (asmanex) dosing in adults

Answer 25

HFA - 200 to 400 mcg bid twisthaler - 110 to 880 mcg qpm

Question 26

inhaled corticosteroids (ICS) usage

Answer 26

prevent and control inflammation in asthma and COPD

Question 27

inhaled corticosteroids (ICS) medications

Answer 27

beclomethasone (qvar) budesonide (pulmicort, pulmicort respules) ciclesonide (alvesco) fluticasone propionate (flovent, armonair diginhaler) fluticasone fuorate (arnuity ellipta) mometasone (asmanex)

Question 28

adverse effects of ICS

Answer 28

oral thrush (candidiasis) cough dysphonia

Question 29

counseling tip of ICS

Answer 29

patients should rinse their mouth and spit after use to prevent oral thrush

Question 30

clinical pearls of ICS

Answer 30

1) most effective long-term control therapy for asthma (improve quality of life, increase lung function, and reduce the risk of exacerbations) 2) may increase the risk of pneumonia in patients with COPD 3) titrate to lowest effective dose 4) pulmicort respules should use jet nebulizer and should not be mixed with other nebulizer medications 5) high doses increase the risk for systemic side effects

Question 31

arformoterol tartrate brand

Answer 31

brovana

Question 32

arformoterol tartrate (brovana) dosage form

Answer 32

nebulizer solution 15 mcg/2mL

Question 33

formoterol brand

Answer 33

perforomist

Question 34

formoterol (perforomist) dosage form

Answer 34

nebulizer solution 20 mcg/2mL

Question 35

indacaterol brand

Answer 35

arcapata neohaler

Question 36

indacaterol (arcapata neohaler) dosage form

Answer 36

neohaler 75 mcg per capsule

Question 37

olodaterol brand

Answer 37

striverdi respimat

Question 38

olodaterol (striverdi respimat) dosage form

Answer 38

respimate 2.5 mcg per inhalation

Question 39

arformoterol tartrate (brovana) dosing in adults

Answer 39

15 mcg inhaled bid COPD only

Question 40

formoterol (perforomist) dosing in adults

Answer 40

20 mcg inhaled bid COPD only unless used in combination with ICS in asthma

Question 41

indacaterol (arcapta neohaler) dosing in adults

Answer 41

75 to 300 mcg inhaled qd COPD only

Question 42

olodaterol (striverdi respimat) dosing in adults

Answer 42

5 mcg (two inhalations) qd COPD only

Question 43

salmeterol brand

Answer 43

serevent

Question 44

salmeterol (serevent) dosage form

Answer 44

diskus 50 mcg/blister

Question 45

salmeterol (serevent) dosing in 4-11 yos

Answer 45

inhale contents of one blister (50 mcg) bid

Question 46

salmeterol (serevent) dosing in adults

Answer 46

50 mcg (one blister) inhaled bid

Question 47

adverse effects of LABA

Answer 47

tachycardia headache tremor hypokalemia

Question 48

box warning for LABA

Answer 48

increased risk of asthma related death for all monotherapy LABA use (should not be used alone for asthma management) increasing hospitalizations in pediatric and adolescent patients

Question 49

clinical pearls of LABAs

Answer 49

prolonged QT seen with intentional overdoses not for acute symptoms may be helpful for exercise induce bronchospasm formoterol and indacaterol capsules should not be taken orall

Question 50

pediatric considerations of LABAs

Answer 50

most children under 4 yos cannot provide sufficient inspiratory flow for adequate lung delivering with a DPI

Question 51

LABA

Answer 51

long acting beta agonists increased cAMP bronchial smooth muscle relaxation and inhibit hypersensitivity mediators from mast cells (histamine and leukotrienes)